文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

靶向髓样细胞表达触发受体-1的细胞外冷诱导RNA结合蛋白衍生小肽减轻失血性休克

An extracellular cold-inducible RNA-binding protein-derived small peptide targeting triggering receptor expressed on myeloid cells-1 attenuates hemorrhagic shock.
PubMed 文献 · J Trauma Acute Care Surg · 2020-01-01
一句话结论小鼠失血性休克模型中,复苏期给予M3肽10 mg/kg可抑制炎症反应并减轻急性肺损伤。

该研究为动物实验,使用C57BL/6小鼠建立失血性休克模型,平均动脉压维持在25-30 mmHg持续90分钟,随后用1 mL生理盐水复苏30分钟。治疗组在复苏期给予10 mg/kg M3肽(一种源自人eCIRP的TREM-1拮抗剂)。复苏后4小时检测显示,M3治疗组血清组织损伤标志物(丙氨酸氨基转移酶、天冬氨酸氨基转移酶、乳酸脱氢酶)及细胞因子(TNF-α、IL-6)的升高被显著抑制;肺组织促炎细胞因子TNF-α、IL-6、IL-1β及趋化因子MIP-2、KC的mRNA表达显著降低;肺损伤评分较溶媒对照组显著降低。作者认为M3肽可能成为失血性休克治疗的潜在辅助手段。

要点

  • 小鼠失血性休克模型中,复苏期给予M3肽10 mg/kg可显著抑制血清丙氨酸氨基转移酶、天冬氨酸氨基转移酶和乳酸脱氢酶升高。
  • M3肽10 mg/kg显著抑制失血性休克小鼠血清TNF-α和IL-6升高。
  • M3肽10 mg/kg显著降低肺组织TNF-α、IL-6、IL-1β及趋化因子MIP-2、KC的mRNA表达。
  • M3肽10 mg/kg显著降低失血性休克小鼠肺损伤评分(与溶媒对照组比较)。
  • 作者认为M3肽可能成为失血性休克治疗的潜在辅助手段。

适用人群与场景

  • C57BL/6小鼠失血性休克模型,平均动脉压维持在25-30 mmHg持续90分钟,随后生理盐水复苏。

处置流程与药物剂量

  • 治疗组在复苏期给予M3肽10 mg/kg(给药途径原文未写明)。
  • 复苏方案:失血性休克90分钟后,用1 mL生理盐水复苏30分钟。

研究设计与关键结果

  • 研究类型:动物实验(小鼠失血性休克模型)。
  • 干预与对照:M3肽10 mg/kg(复苏期给药)vs 溶媒对照,另设假手术组。
  • 主要结果:血清组织损伤标志物(丙氨酸氨基转移酶、天冬氨酸氨基转移酶、乳酸脱氢酶)及细胞因子(TNF-α、IL-6)在溶媒组较假手术组升高,M3治疗组该升高被显著抑制。
  • 肺组织mRNA:溶媒组HS小鼠肺TNF-α、IL-6、IL-1β及趋化因子MIP-2、KC表达显著增加,M3治疗组显著降低。
  • 肺损伤评分:M3治疗组较溶媒组显著降低。

证据类型、等级与局限

  • 证据类型:动物实验(小鼠)。
  • 作者结论:新型eCIRP衍生TREM-1拮抗剂M3可能成为失血性休克治疗的潜在辅助手段。
  • 局限:原文未报告局限性

对床旁实践的改变

  • 原文为小鼠实验,作者认为M3肽可能成为失血性休克治疗的潜在辅助手段。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Extracellular cold-inducible RNA-binding protein (eCIRP) is a damage-associated molecular pattern, which is released into the circulation after hemorrhagic shock (HS). Recently, we discovered that triggering receptor expressed on myeloid cells-1 (TREM-1) serves as a new receptor of eCIRP to exaggerate inflammation. Here, we hypothesize that by inhibiting the interaction between eCIRP and TREM-1 with the use of a novel short peptide derived from human eCIRP known as M3, we can inhibit the inflammatory response and acute lung injury in HS.

METHODS: Hemorrhagic shock was induced using C57BL/6 mice by cannulating both femoral arteries. One femoral artery was used for removal of blood while the other was used for continuous monitoring of mean arterial blood pressure. The mean arterial pressure of 25 mm Hg to 30 mm Hg was maintained for 90 minutes, followed by a resuscitation phase of 30 minutes with 1 mL of normal saline. The treatment group was given 10 mg/kg of M3 during the resuscitation phase. Four hours after resuscitation, serum and lungs were collected and analyzed for various injury and inflammatory markers by using colorimetry, real-time polymerase chain reaction, and enzyme-linked immunosorbent assay.

RESULTS: There was an increase in the serum levels of tissue injury markers (alanine aminotransferase, aspartate aminotransferase, and lactate dehydrogenase) as well as cytokines (TNF-α and IL-6) when comparing the vehicle group versus the sham group. This increase was significantly inhibited in the M3-treated group. The mRNA expression of proinflammatory cytokines TNF-α, IL-6, and IL-1β and the chemokines MIP-2 and KC in lungs was significantly increased in the vehicle-treated HS mice, while their expression was significantly decreased in M3-treated HS mice. Finally, M3 treatment significantly decreased the lung injury score compared with vehicle-treated HS mice.

CONCLUSION: The novel eCIRP-derived TREM-1 antagonist (M3) can be a potential therapeutic adjunct in the management of hemorrhagic shock.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Gurien SD, Aziz M, Cagliani J, et al. An extracellular cold-inducible RNA-binding protein-derived small peptide targeting triggering receptor expressed on myeloid cells-1 attenuates hemorrhagic shock. J Trauma Acute Care Surg. 2020. PMID: 32453257. doi:10.1097/TA.0000000000002664

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。